AMENDMENTS TO THE CLAIMS

1-23. (Previously cancelled)

24. (Currently canceled)

25-27. (Previously canceled)

28. (Currently canceled)

29. (Previously canceled).

30-36. (Currently canceled)

37-39. (Previously canceled).

40. (Currently canceled)

41. (Previously canceled).

42-43. (Currently canceled)

44-45. (Previously canceled)

46-49. (Currently canceled)

50. (New) A pharmaceutical composition for use in breast cancer therapy in humans, said composition comprising:

(a) at least one antineoplastic agent selected from the group consisting of epirubicin and docetaxel, and a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, or combination thereof; and

(b) aromatase inhibitor exemestane and a pharmaceutically acceptable carrier, pharmaceutically acceptable diluent, or combination thereof,

wherein said antineoplastic agent and said aromatase inhibitor are present in superadditive antitumor effective amounts.

51. (New) The pharmaceutical composition according to claim 50, wherein the composition comprises two antineoplastic agents.

52. (New) The pharmaceutical composition according to claim 50, wherein the antineoplastic agent is epirubicin.

53. (New) The pharmaceutical composition according to claim 50, wherein the antineoplastic agent is docetaxel.

54. (New) The pharmaceutical composition, according to claim 50, wherein an effective antineoplastic amount of epirubicin ranges from about 20 mg/m^2 to about 200 mg/m^2, and an effective antineoplastic amount of docetaxel ranges from about 50 mg/m^2 to about 100 mg/m^2.

55. (New) The pharmaceutical composition according to claim 54, wherein when administered orally, the amount of aromatase inhibitor exemestane ranges from about 5 to about 200 mg.

56. (New) The pharmaceutical composition according to claim 55, wherein the amount of aromatase inhibitor exemestane ranges from about 10 to about 25 mg.

57. (New) The pharmaceutical composition according to claim 54, wherein when administered parenterally, the amount of aromatase inhibitor exemestane ranges from about 50 to about 500 mg.

58. (New) The pharmaceutical composition according to claim 50, wherein when administered subcutaneously, the amount of aromatase inhibitor exemestane ranges about 20 mg/Kg/day.

59. (New) The pharmaceutical composition according to claim 58, wherein when administered intravenously, the amount of antineoplastic epirubicin is 1 or 3 mg/Kg/week.

60. (New) The pharmaceutical composition according to claim 58, wherein when administered intravenously, the amount of antineoplastic docetaxel ranges from about 1.5 mg/Kg/week.

61. (New) A method for treating breast cancer in humans, said method comprising administering to a human in need thereof (a) at least one antineoplastic agent selected from the group consisting of epirubicin and docetaxel; and (b) an aromatase inhibitor exemestane, in amounts effective to produce a superadditive antitumor effect.

62. (New) The method according to claim 61, wherein the method comprising administering two antineoplastic agents.

63. (New) The method according to claim 61, wherein the antineoplastic agent is epirubicin.

64. (New) The method according to claim 61, wherein the antineoplastic agent is docetaxel.

65. (New) The method according to claim 61, wherein an effective antineoplastic amount of epirubicin ranges from about 20 mg/m^2 to about 200 mg/m^2 and an effective antineoplastic amount of docetaxel ranges from about 50 mg/m^2 to about 100 mg/m^2.

66. (New) The method according to claim 65, wherein when administered orally, the amount of aromatase inhibitor exemestane ranges from about 5 to about 200 mg.

67. (New) The pharmaceutical composition according to claim 66, wherein the amount of aromatase inhibitor exemestane ranges from about 10 to about 25 mg.

68. (New) The method according to claim 65, wherein when administered parenterally, the amount of aromatase inhibitor exemestane ranges from about 50 to about 500 mg.

69. (New) The method according to claim 61, wherein when administered subcutaneously, the amount of aromatase inhibitor exemestane is about 20 mg/Kg/day.

70. (New) The method according to claim 69, wherein when administered intravenously, the amount of antineoplastic epirubicin is 1 or 3 mg/Kg/week.

71. (New) The method according to claim 69, wherein when administered intravenously, the amount of antineoplastic docetaxel is about 1.5 mg/Kg/week.

72. (New) A method for lowering the side effects in humans caused by breast cancer therapy with an antineoplastic agent, said method comprising administering to a human in need thereof a pharmaceutical composition comprising (a) at least one antineoplastic agent selected from the group consisting of epirubicin and docetaxel; and (b) aromatase inhibitor exemestane, wherein said agent and said inhibitor is present in a quantity to produce a superadditive antitumor effect.

73. (New) The method according to claim 72, wherein the method comprising administering two antineoplastic agent.

74. (New) The method according to claim 72, wherein the antineoplastic agent is epirubicin.

75. (New) The method according to claim 72, wherein the antineoplastic agent is docetaxel.

76. (New) The method according to claim 72, wherein an effective antineoplastic amount of epirubicin ranges from about 20 mg/m^2 to about 200 mg/m^2 and an effective antineoplastic amount of docetaxel ranges from about 50 mg/m^2 to about 100 mg/m^2.

77. (New) The method according to claim 76, wherein the neoplastic agent and the aromatase inhibitor exemestane is administered orally, and is administered from about 5 to about 200 mg.

78. (New) The method according to claim 72, wherein the amount of aromatase inhibitor exemestane ranges from about 10 to about 25 mg.

79. (New) The method according to claim 76, wherein the antineoplastic agent and the steroidal aromatase inhibitor exemestane are administered parenterally, and the aromatase inhibitor is administered from about 5 to about 500 mg.

80. (New) The method according to claim 72, wherein when administered subcutaneously, the amount of aromatase inhibitor exemestane is about 20 mg/Kg/day.

81. (New) The method according to claim 80, wherein when administered intravenously, the amount of antineoplastic epirubicin is 1 or 3 mg/Kg/week.

82. (New) The pharmaceutical composition according to claim 80, wherein when administered intravenously, the amount of antineoplastic docetaxel is about 1.5 mg/Kg/week.